The American Society of Hematology (ASH) conference will be here in a few short weeks (December 7-10 in New Orleans). There are over 160 oral presentations and over 500 poster presentations for multiple myeloma alone. With much excitement about the expanding variety of newer therapy targets, myeloma specialists are now preparing to share their research at this important conference. We look forward to speaking with myeloma experts at ASH and will bring you excerpts from our discussions with them. We will resume our weekly interviews at the beginning of the new year and in the meantime, we will introduce new products we’ve had under development.
As a side note, our interview with Dr. David Siegel was rescheduled for later in January due to a patient emergency that came up last Friday.
We look forward to learning more about the very latest in research and helping connect you with top myeloma experts.
Why Join Myeloma Clinical Trials?
As myeloma patients, we all want to find a cure. Until a cure is found, we want access to treatments that improve outcomes and extend life. The only way to achieve both is to participate in clinical trials.
Today, less than 5% of myeloma patients join clinical trials. By joining clinical trials in greater numbers, we can dramatically cut research time to find better treatments and drive towards a cure. Many of the myeloma specialists have told us that “yesterday’s trials are today’s treatments.”
To learn more about how to join a clinical trial, click the button below.
What Patients Are Saying
“Thank you, thank you, thank you for this incredible series. It is so very valuable and informative. It is just so wonderful to be able to listen to all of the different, yet similar perspectives of the brilliant minds who work so tirelessly on behalf of MM patients.”
“Your interviews and their transcripts are invaluable aids in understanding the state of the art of myeloma research and treatment. They also give us an idea of what the treatment philosophies are at various institutions. I read and listen to them religiously. You are revolutionizing myeloma patients’ knowledge and relationship to their doctors. Thanks so much for your great work!”